DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 195 filers reported holding DYNE THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.30 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $43,544,613 | +119.8% | 1,233,908 | +76.8% | 0.42% | +128.6% |
| Q1 2024 | $19,814,148 | +242.1% | 697,927 | +60.2% | 0.18% | +188.9% |
| Q4 2023 | $5,792,496 | +92.5% | 435,526 | +29.7% | 0.06% | +80.0% |
| Q3 2023 | $3,009,521 | -30.1% | 335,884 | -12.2% | 0.04% | -31.4% |
| Q2 2023 | $4,303,980 | -6.1% | 382,576 | -42.6% | 0.05% | -28.2% |
| Q2 2022 | $4,582,000 | -41.5% | 666,997 | -18.0% | 0.07% | -44.1% |
| Q1 2022 | $7,839,000 | +28.1% | 813,139 | +58.0% | 0.13% | +44.3% |
| Q4 2021 | $6,119,000 | +74.3% | 514,601 | +138.0% | 0.09% | +54.4% |
| Q3 2021 | $3,511,000 | -25.0% | 216,201 | -2.8% | 0.06% | -34.5% |
| Q2 2021 | $4,679,000 | -21.2% | 222,374 | -41.9% | 0.09% | -34.1% |
| Q1 2021 | $5,940,000 | -42.4% | 382,493 | -22.1% | 0.13% | -51.6% |
| Q4 2020 | $10,311,000 | +91.4% | 490,986 | +84.0% | 0.27% | +54.2% |
| Q3 2020 | $5,387,000 | – | 266,799 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,074,787 | $27,594,667 | 32.85% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $65,852,330 | 32.36% |
| FCPM III SERVICES B.V. | 6,131,079 | $81,543,351 | 24.03% |
| Atlas Venture Life Science Advisors, LLC | 9,885,449 | $131,476,472 | 15.66% |
| TCG Crossover Management, LLC | 1,650,150 | $21,946,995 | 2.43% |
| Logos Global Management LP | 1,880,000 | $25,004,000 | 2.33% |
| VR Adviser, LLC | 2,173,913 | $28,913,043 | 1.98% |
| Octagon Capital Advisors LP | 792,945 | $10,546,169 | 1.69% |
| Vivo Capital, LLC | 1,035,136 | $13,767,309 | 1.13% |
| ACUTA CAPITAL PARTNERS, LLC | 147,836 | $1,966,219 | 1.11% |